Scientific deep-dive

Semaglutide and Alzheimer's: The Trials Came Back Negative

Two randomized trials in 3,808 people with early Alzheimer's found no difference in cognitive decline at two years. Both were discontinued for negative clinical outcome. The 45% figure came from studies measuring something else.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·2 citations

For three years the most exciting claim about GLP-1 drugs was that they might slow Alzheimer’s disease. Two large randomized trials set out to test it directly, enrolled 3,808 people, measured their main outcome at two years, and found nothing. Both were discontinued for negative clinical outcome.[1]

What the trials did

The evoke and evoke+ trials randomized adults with early-stage symptomatic Alzheimer’s disease to placebo or oral semaglutide 14 mg, for as long as 156 weeks, and read the primary outcome at week 104. Participants had a mean age of 72.2 and a mean CDR-SB score of 3.7 at baseline.[1] CDR-SB is a standard measure of dementia severity. Higher is worse, and the outcome that matters is how much the score changes over time.

Change in CDR-SB score from baseline to week 104. Lower change means slower decline. Figures from the published report.
TrialSemaglutidePlaceboDifference
evoke (n=1,855)2.32.3−0.08 (95% CI −0.35 to 0.20), p=0.57
evoke+ (n=1,953)2.22.10.10 (95% CI −0.17 to 0.38), p=0.46

Both confidence intervals sit squarely across zero and the point estimates go in opposite directions. Neither trial narrowly missed, and neither looks like one that more participants would have rescued. The result is flat in nearly four thousand people.

In evoke, CDR-SB scores rose 2.3 points on semaglutide and 2.3 points on placebo.

Why the earlier signals looked so promising

The earlier evidence was not fabricated, and it was widely reported. We covered it in three analyses, three answers: a meta-analysis of 26 trials found a 45% reduction in dementia outcomes, a cohort of 396,963 patients found 33%, and a continuously updated review found nothing significant and graded its own certainty as low.

The pattern is a familiar one, and Parkinson’s disease has followed a similar course with exenatide. Dementia outcomes in those trials were incidental: they were recorded as adverse events in studies designed around diabetes and cardiovascular disease, in people who were not selected for cognitive symptoms. Cohort studies compared people prescribed a newer drug against people who were not, and the difference between those groups is never only the drug. We take that apart in the cancer cohorts, where the same mechanism produced a 91% mortality difference that evaporated against a fair comparator.

The review that found nothing was the one that was right. It reported no significant effect and graded its certainty low, which is a much less quotable finding than 45%. When three analyses disagree, the least exciting one is not automatically correct. Here, though, it is the one the randomized trial went on to agree with.

A second drug, a third negative primary endpoint

A different GLP-1 drug has now failed the same question in a separate trial. ELAD randomized 204 people with mild to moderate Alzheimer’s disease and no diabetes to daily liraglutide or placebo for 52 weeks, with brain imaging and detailed cognitive testing.[2]

Its primary outcome was the rate of glucose metabolism in the brain, measured by PET. There was no significant difference (−0.17, with a 95% confidence interval from −0.39 to 0.06; P = 0.14).

One secondary measure did favor liraglutide, and the paper labels it carefully. A score on the executive-function domain of the Alzheimer’s Disease Assessment Scale came out better on the drug (0.15, 95% CI 0.03–0.28) at an unadjusted P of 0.01. Unadjusted means not corrected for the number of secondary outcomes tested, and a trial measuring imaging, cognition, function and safety tests a great many. The authors are being transparent by saying so; a summary that drops the word will not be.

The pattern across the two programs is now consistent, and it is the pattern that should be believed: three primary endpoints, three failures, two different drugs. Positive findings survive in secondary and exploratory measures, which is where positive findings usually survive after a primary endpoint has gone the other way. The trials and the earlier observational studies are side by side in our dementia reading list.

A smaller trial in a different population reported a similar shape, with three cognitive domains improving and one surviving adjustment at exactly the significance threshold (see three domains improved, then one). Nothing here rules out a real cognitive effect, in either direction. It does mean that every properly powered test of one has so far come back negative on the question it set out to ask. What the trials mean for everyday brain fog on a GLP-1 is a separate question.

What the trials do not settle

Overclaiming in the skeptical direction would be the same error as overclaiming in the hopeful one, so it matters what these trials leave open.

  • This tested treatment, not prevention. Participants already had symptomatic Alzheimer’s. Whether taking a GLP-1 in midlife changes the odds of developing dementia decades later is a different question and remains open.
  • It tested oral semaglutide at 14 mg. Not injectable semaglutide, not tirzepatide, and not the higher doses used for weight management.
  • Early-stage symptomatic disease is a specific window. Most Alzheimer’s drug trials fail in it, and that is a hard place to show benefit.
  • It says nothing about cognition in people without dementia, which is a separate and much murkier literature.

On safety, the numbers went the other way

Adverse events were more common on semaglutide (91.2% against 84.8%), which is consistent with everything known about this drug class and mostly reflects gastrointestinal effects.[1]

But of five deaths that investigators judged related to treatment, one was in the semaglutide group and four were in the placebo group.[1] Nothing should be concluded from five events. We report them because a failed trial in an elderly population is exactly the setting where a safety scare tends to be assembled from selective reporting, and these numbers do not support one.

The authors’ own summary is that safety and tolerability in early Alzheimer’s were consistent with studies in other indications.[1] The drug behaved as expected. It simply did not do the thing being tested. Where this result sits in the wider case for GLP-1s as longevity drugs is laid out in are GLP-1s longevity drugs?.

Frequently Asked Questions

No. Two randomized trials in 3,808 people with early-stage symptomatic Alzheimer's found no difference in cognitive decline at two years. CDR-SB change was 2.3 against 2.3 in one trial and 2.2 against 2.1 in the other, with both confidence intervals crossing zero. Both trials were discontinued for negative clinical outcome.
Those were meta-analyses of trials that recorded dementia incidentally while studying something else, and cohort studies comparing people prescribed a newer drug against people who were not. A continuously updated review of the same evidence found nothing significant and graded its certainty as low, and the randomized trials agreed with that one.
It does not settle that. These trials tested treatment of people who already had symptomatic Alzheimer's, not prevention in healthy people years earlier. That question remains open, and a negative treatment trial does not answer it either way.
Adverse events were more frequent on semaglutide, 91.2% against 84.8%, consistent with its known gastrointestinal profile. Of five deaths judged treatment-related by investigators, one was on semaglutide and four were on placebo. The authors call the safety record in line with semaglutide’s other uses.
Unknown, and there is no result to point to. These trials used oral semaglutide at 14 mg. Whether a different formulation or dose would perform differently has not been tested in this population.

References

  1. 1.Cummings JL, Atri A, Sano M, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+) The Lancet. 2026. PMID: 41865758.
  2. 2.Edison P, Femminella GD, Ritchie C, et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial Nature Medicine. 2026. PMID: 41326666.

GLP-1s and Epilepsy Risk

People on GLP-1 drugs developed epilepsy less often than those on a different diabetes drug (hazard ratio 0.84). But the association was strongest at one year and weaker at five, which is backwards for neuroprotection.

5 min read

When the Primary Endpoint Fails and a Secondary Doesn't

A randomized trial in 72 people with major depressive disorder found no effect on executive function, its primary outcome. A secondary cognition measure cleared p=0.03, and that is the one that will be reported.

5 min read

Semaglutide and Motivation

Semaglutide reduced how heavily people with depression discounted effort, while leaving their sensitivity to probability unchanged. That dissociation is what makes the finding hard to dismiss.

5 min read

Phentermine and a GLP-1 Together: What the Labels and Trials Show

Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.

10 min read

GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days

Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.

7 min read

Who Loses More Weight on a GLP-1?

Across 64 randomized trials, the only subgroup difference was sex: women lost 10.9% against 6.8% for men. Age, race, ethnicity, starting BMI and starting HbA1c made no significant difference.

5 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

From $59/mo + membership

Get started →
Read full review →
6.4

MyDrHank

An oral route if you will not self-inject

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →